PLoS ONE · 2015 · 19 citations · 20 references
PharmacyPharmacologyPharmacotherapyMolecular PharmacologyPediatric TherapeuticsPharmacodynamicsAcute Lung InjuryNeonatal Drug TherapyNeonatal PharmacologyNeonatal PharmacotherapyAcute Lung Injury PathophysiologyHistone AcetylationHistone-lysine AcetylationHistopathology Of Lung InjuryInflammatory Lung InjuryLung DiseasesMechanisms Of Lung ToxicityValproic Acid
OBJECTIVE: Histone acetylation and deacetylation may play a role in the pathogenesis of inflammatory lung diseases. We evaluated the preventive effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on neonatal hyperoxic lung injury. METHODS: Forty newborn rat pups were randomized in normoxia, normoxia+VPA, hyperoxia and hyperoxia+VPA groups. Pups in the normoxia and normoxia+VPA groups were kept in room air and received daily saline and VPA (30 mg/kg) injections, respectively, while those in hyperoxia and hyperoxia+VPA groups were exposed to 95% O2 and received daily saline and VPA (30 mg/kg) injections for 10 days, respectively. Growth, histopathological, biochemical and molecular biological indicators of lung injury, apoptosis, inflammation, fibrosis and histone acetylation were evaluated. RESULTS: VPA treatment during hyperoxia significantly improved weight gain, histopathologic grade, radial alveolar count and lamellar body membrane protein expression, while it decreased number of TUNEL(+) cells and active Caspase-3 expression. Expressions of TGFβ3 and phospho-SMAD2 proteins and levels of tissue proinflammatory cytokines as well as lipid peroxidation biomarkers were reduced, while anti-oxidative enzyme activities were enhanced by VPA treatment. VPA administration also reduced HDAC activity while increasing acetylated H3 and H4 protein expressions. CONCLUSIONS: The present study shows for the first time that VPA treatment ameliorates lung damage in a neonatal rat model of hyperoxic lung injury. The preventive effect of VPA involves HDAC inhibition.
20
Identification of a p53-dependent negative response element in the bcl-2 gene.
Toshiyuki Miyashita, Masayoshi Harigai, Masahito Hanada et al. · PubMed · 1994 · 747 citations
Hyeon Ju Kim, Michael K. Rowe, Ming Ren et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 563 citations
Michael T. Hemann, Scott W. Lowe · Cell Death and Differentiation · 2006 · 369 citations